PMC:7283670 / 63163-64113
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T366 | 67-69 | Disease | denotes | GS | http://purl.obolibrary.org/obo/MONDO_0005773 |
| T367 | 128-136 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T583 | 43-51 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T584 | 251-253 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T585 | 444-448 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 3, 4 |
| T586 | 620-624 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 3, 4 |
| T587 | 649-655 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | Active |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T162 | 33-42 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T163 | 55-65 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T164 | 67-69 | Chemical | denotes | GS | http://purl.obolibrary.org/obo/CHEBI_73516 |
| T165 | 184-194 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T166 | 296-306 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T167 | 471-481 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T168 | 892-896 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T640 | 0-456 | Sentence | denotes | Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5. |
| T641 | 457-648 | Sentence | denotes | Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10. |
| T642 | 649-950 | Sentence | denotes | Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1893 | 80-92 | Species | denotes | participants | Tax:9606 |
| 1894 | 315-327 | Species | denotes | participants | Tax:9606 |
| 1895 | 491-503 | Species | denotes | participants | Tax:9606 |
| 1896 | 748-760 | Species | denotes | participants | Tax:9606 |
| 1897 | 823-835 | Species | denotes | participants | Tax:9606 |
| 2064 | 55-65 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 2065 | 184-194 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 2066 | 296-306 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 2067 | 471-481 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 2129 | 107-126 | Disease | denotes | coronavirus disease | MESH:D018352 |
| 2130 | 128-136 | Disease | denotes | COVID‐19 | MESH:C000657245 |